BridgeBio reported positive top-line results from Propel 3: oral infigratinib improved annualized height velocity versus placebo in children with achondroplasia and achieved significant secondary endpoints. The Phase III win positions infigratinib as a rival to existing therapies and supports a planned regulatory submission later this year. BioCentury and MedCity News coverage highlighted the drug’s oral dosing as a differentiator versus injectable competitors. Company commentary and market moves reflected investor optimism about an additional treatment option for a rare growth disorder where few therapies exist.